LV15518A - Derivatives of aziridine-2-carboxamide as inhibitors of thioredoxin reductase, their synthesis, anti-cancer and anti-metastatic effect - Google Patents

Derivatives of aziridine-2-carboxamide as inhibitors of thioredoxin reductase, their synthesis, anti-cancer and anti-metastatic effect

Info

Publication number
LV15518A
LV15518A LVP-19-08A LV190008A LV15518A LV 15518 A LV15518 A LV 15518A LV 190008 A LV190008 A LV 190008A LV 15518 A LV15518 A LV 15518A
Authority
LV
Latvia
Prior art keywords
aziridine
carboxamide
derivatives
inhibitors
cancer
Prior art date
Application number
LVP-19-08A
Other languages
Latvian (lv)
Inventor
Raivis ŽALUBOVSKIS
Jekaterīna IVANOVA
Ilona Domračeva
Iveta KAŅEPE-LAPSA
Ivars KŪMS
Original Assignee
Latvijas Organiskās Sintēzes Institūts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Latvijas Organiskās Sintēzes Institūts filed Critical Latvijas Organiskās Sintēzes Institūts
Priority to LVP-19-08A priority Critical patent/LV15518A/en
Priority to PCT/IB2019/060350 priority patent/WO2020170022A1/en
Publication of LV15518A publication Critical patent/LV15518A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/16—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with acylated ring nitrogen atoms
    • C07D203/18—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with acylated ring nitrogen atoms by carboxylic acids, or by sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to novel potentially therapeutic compounds that contain 1-acyl derivatives of aziridine-2-carboxamide and their analogues with anticancer, antiproliferative and antimetastatic properties.
LVP-19-08A 2019-02-18 2019-02-18 Derivatives of aziridine-2-carboxamide as inhibitors of thioredoxin reductase, their synthesis, anti-cancer and anti-metastatic effect LV15518A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
LVP-19-08A LV15518A (en) 2019-02-18 2019-02-18 Derivatives of aziridine-2-carboxamide as inhibitors of thioredoxin reductase, their synthesis, anti-cancer and anti-metastatic effect
PCT/IB2019/060350 WO2020170022A1 (en) 2019-02-18 2019-12-02 Derivatives of aziridine-2-carboxamide as inhibitors of thioredoxin reductase, their synthesis, anti-cancer and anti-metastatic effect

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LVP-19-08A LV15518A (en) 2019-02-18 2019-02-18 Derivatives of aziridine-2-carboxamide as inhibitors of thioredoxin reductase, their synthesis, anti-cancer and anti-metastatic effect

Publications (1)

Publication Number Publication Date
LV15518A true LV15518A (en) 2020-08-20

Family

ID=65598692

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-19-08A LV15518A (en) 2019-02-18 2019-02-18 Derivatives of aziridine-2-carboxamide as inhibitors of thioredoxin reductase, their synthesis, anti-cancer and anti-metastatic effect

Country Status (2)

Country Link
LV (1) LV15518A (en)
WO (1) WO2020170022A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2731264A1 (en) * 1977-07-11 1979-02-01 Boehringer Mannheim Gmbh NEW 1-ACYL-2-CYANAZIRIDINE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS
JPH11322593A (en) * 1998-03-19 1999-11-24 Sagami Chem Res Center Anticancer agent and tubuline inhibitor containing acetamide derivative, and new acetamide derivative

Also Published As

Publication number Publication date
WO2020170022A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
MX2023005804A (en) Pyridazinones as parp7 inhibitors.
MX2022005216A (en) Pyridazinones as parp7 inhibitors.
PH12016502504A1 (en) Mnk inhibitors and methods related thereto
PH12016501578A1 (en) Pharmaceutical compounds
NZ742742A (en) Compositions and methods for inhibiting arginase activity
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
CY1119900T1 (en) Bilateral Buprenorphine And Its Use In The Treatment Of Gastrointestinal Disorders
WO2017223280A3 (en) Compositions and methods for the delivery of therapeutics
MX2020006365A (en) Quinazolinones as parp14 inhibitors.
MX353299B (en) Methods and compositions relating to p62 for the treatment and prophylaxis of cancer.
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
MX2018009794A (en) Intermediates in the synthesis of eribulin and related methods of synthesis.
MX2017012102A (en) Bifunctional cytotoxic agents containing the cti pharmacophore.
MY181641A (en) Amino pyran ring derivative and composition and use thereof
MX2017010297A (en) C-3 novel triterpenone with c-28 reverse amide derivatives as hiv inhibitors.
MX2019006863A (en) Heparanase inhibitors and use thereof.
IN2015CH01182A (en)
MX2021008225A (en) Compositions and methods for treatment of abnormal cell growth.
MX2019008375A (en) Thiobenzoimidazole as fungicides.
IL279168B (en) Process for the preparation of eribulin
LV15518A (en) Derivatives of aziridine-2-carboxamide as inhibitors of thioredoxin reductase, their synthesis, anti-cancer and anti-metastatic effect
JOP20210327A1 (en) Novel spirobicyclic intermediates
PH12017501897A1 (en) 2-thiopyrimidinones
JOP20200104A1 (en) Btk inhibitor compounds
PH12017501147A1 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs